Benjamin F. Edwards & Company’s Viking Therapeutics VKTX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$7K	Buy	+140	New	+$9.18K	﹤0.01%	1811

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Benjamin F. Edwards & Company's VKTX Position: Q2 2024 in Review

Benjamin F. Edwards & Company opened a new position in Viking Therapeutics (VKTX) in Q2 2024: 140 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #1811 among its holdings.

387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

Benjamin F. Edwards & Company held 140 shares of Viking Therapeutics worth $7K as of Q2 2024.
Viking Therapeutics was a new Benjamin F. Edwards & Company position in Q2 2024.
Viking Therapeutics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1811 holding.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.